Isn’t it time to lose weight and breathe a sigh of relief? Several diet pills have been formulated keeping in mind the grave threat posed by these two health condition. Amongst the pile of weight loss pills available in the market, Rimonabant has carved its sphere for effective weight loss results.
Are you having troubles while climbing up the stairs, or walking down to the nearest mall or park? Is it because of your excessive weight? Check with your doctor immediately because you may be a victim of overweight or obesity. Being overweight and obese should be understood as two different health conditions. Overweight can be simply understood as having more bodily mass than required in proportion to your height and age. Whereas, obesity is something even more serious as it is an extension of overweight. Both these health conditions can throw you in the hands of health hazards such as high cholesterol, high blood pressure amid others.
Rimonabant is an effective appetite suppressant which is preferred by many doctors’ worldwide. It received approval in the EU as an effectual appetite suppressant. It is also marketed under the trade name of Acomplia, Slimona and Onitone.
The principle on which this weight loss medication works is the obstruction of hunger signals to the brain. Specific neuro-transmitters located in the brain region are responsible for regulating appetite in the body. Consumption of Rimonabant diet pills basically hinders the functioning of these specific neuro-transmitters, which is consequential in the reduction of appetite. Reduction in your normal appetite means that you would eat in small portions. This process is thereby beneficial in weight loss.
Usually Rimonabant medication is suggested to be combined with a proper diet plan and a regular workout to fetch effective weight loss results. These weight loss pills can be accessed in the strengths of 20mg, and 37.5mg. 20mg Rimonabant diet drug is the normal recommended dosage for use. However, it is always advisable to speak with your doctor prior to initiating Rimonabant weight loss, to well-acquaint yourself about the suitable dosage and usage directions.
Ensure adequate precautionary measures while using Rimonabant diet pills, to attain optimistic weight loss.
Rimonabant has along been in the news for its effectiveness in weight loss. Since then, Rimonabant has reigned the weight loss market. It is one reason why most doctors prefer Rimonabant over other weight loss medications like Phentermine.
But is it worth a try? Success stories of Rimonabant diet drug have displayed noteworthy weight loss results. Rimonabant is an oral prescription medication which works on the neuro-transmitters, which are responsible for regulating appetite in the body. These neuro-transmitters located in the brain region, send signals of hunger. Amongst obese or overweight individuals, these transmitters tend to be overactive. Consumption of Rimonabant basically obstructs the over-activity of these neuro-transmitters, thereby reducing the normal appetite of an obese or an overweight individual.
This effective weight loss medication, Rimonabant is usually recommended for obese who have BMI 30 or overweight who have BMI27 with health risk factors. In order to get well-acquainted whether Rimonabant is suitable for you or not, speak with your doctor.
With Rimonabant, it is available in two strengths of 20mg, and 37.5mg. Your doctor can suggest an apt dosage in accordance to your medical condition and requirement. Each dose of this medication is to be consumed with a glassful of water. The reason, it is a prescription medication one should not alter the recommended dosage without medical consultation. This medication is suggested to be accompanied with a proper diet plan and regular workout regime in order to achieve optimistic weight loss results.
Other brand names of Rimonabant diet drug are Acomplia and Slimona. It is also available under the name of Obitone.
This diet drug, Rimonabant can be accessed easily by means of online pharmacies. Buy Rimonabant online which can make your purchase expedient and also you a lot of time. Some of these also give you the benefit of online consultation and prescription facility too.
Acomplia Rimonabant , discovered and developed by French pharmaceutical company Sanofi-Synthelabo, is a new drug thas has shown great promise in trials for the treatment of obesity and related metabolic risk factors. Rimonabant is already on the market in Europe, being sold under the trade name Acomplia , and is awaiting approval in the United States.The FDA would not permit rimonabant to be sold as Acomplia in the U.S., and Sanofi is now hoping to market it in the United States as Zimulti.
Rimonabant Acomplia works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System) , believed to play a critical role in the regulation of food intake and energy expenditure. The receptors are present on the surfaces of many cells throughout the body, including fat cells — which are involved in lipid and glucose metabolism — and those in the hypothalamus, the brain region that is thought to determine appetite. Cannabinoids, chemical compounds produced by your body, latch on to the CB1 receptors, which are overactive in overweight and obese individuals, sending out a signal that prompts people to eat more. Researchers wondered whether a drug that halted this action might curb appetite, and in 2001, the first animal study was conducted at the National Institute of Alcohol Abuse and Alcoholism in Bethesda, Md. In the study, genetically altered mice that lacked cannabinoid receptors ate less than their litter mates, even after 18 hours of fasting. When the normal mice were given rimonabant, which blocked their CB1 receptors, the mice reduced their food intake. In 2002, Sanofi-Synthelabo began human tests.
Acomplia works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or cigarette pangs more manageable. Much of the excitement about Acomplia stems from early results suggesting that the blocking of signals that control cravings not only facilitates weight loss, but that it also improves cardiovascular/ metabolic risk factors in overweight/obese patients.In the RIO-Lipids trial, weight loss was accompanied by a decrease in waist size of 3.4 inches demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease.Dramatic improvements also were reported in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides.Improvements in glucose tolerance and insulin levels were also reported. Approximately half of the patients diagnosed at the start of the study with metabolic syndrome, who received the higher 20 mg daily dose of Acomplia, no longer had this condition at the conclusion of the trial.
A system in the body that plays a role in getting the “munchies” may be the latest battleground in the war on obesity , according to experts at a presentation sponsored by the American Medical Association.The endocannabinoid system affects many body processes, including the control of food intake and metabolic functions such as energy, sugar, and fats. Studies have shown that the endocannabinoid system is revved up in people who are obese, causing weight gain and its related risks.
“What many people are looking at as a lack of willpower could have some physical basis,” says Louis J. Aronne, MD, director of the Comprehensive Weight Control Program at New York Presbyterian Hospital-Weill Cornell Medical Center and a clinical professor of medicine at Weill Medical College of Cornell University in New York. Simply put, when the endocannibinoid system is overactive, people eat more, leading to weight gain.
But blocking the endocannabinoid system may do more than just reduce weight; it may also reduce related risk factors. Because this system also affects metabolic functions, putting the lid on it fights risk factors that lead to diabetes.
Five drugs are being developed that block the endocannabinoid system, including Acomplia, the “antimunchies” drug, so-named because it acts like marijuana in reverse, curbing appetite.
EC system 101
When your endocannabinoid system is overactive, the deck is stacked against you. “Its effect on the brain is to increase hunger and decrease satiety, and drive the desire for palatable food,” he explains. “In the gastrointestinal tract, it interacts with other hormones … to make you feel hungrier.”
What’s more, it impairs the cells’ ability to use blood sugar. This sets the stage for diabetes.
Studies in both animals and humans show that when the endocannibinoid system is stimulated, it leads to weight gain, increases body fat, and slows the action of insulin. Taken together, these effects are called the metabolic syndrome, which predisposes a person to developing heart disease and diabetes.
Is Blocking the EC System a Panacea?
Soon after discovering the endocannabinoid system, researchers began to find sites all over the body called cannabinoid receptors. Blocking these receptors may rein in the overactive endocannabinoid system and reduce weight as well as improve other related risk factors. Acomplia is designed to do just that.
A recent study published in The Journal of the American Medical Association showed that people who took Acomplia were able to lose weight, maintain their weight loss, reduce the level of fats in the blood and fat deposits, and improve insulin action as long as they took the drug, thus reducing their risk factors for heart disease and diabetes.
Drugs that block the endocannabinoid system may provide “one more tool in the tool box to deal with obesity,” says Sharonne N. Hayes, MD, director of the Women’s Heart Clinic at the Mayo Clinic in Rochester, Minn., and an associate professor of medicine and cardiovascular disease at the Mayo Clinic College of Medicine, also in Rochester.
“Right now all we have to treat the metabolic syndrome is lifestyle changes such as diet and exercise, and just losing 10% of body weight that can be very effective, but there are many people who can’t meet this goal,” she says, “If we had a tool that had some impact on the underlying [cause], that would be great,” she says.
From what we see here, Rimonabant shows great results and promises in the fight against obesity. We learned until today that Rimonabant is the key in winning this war and soon we’ll see more and more people satisfied by the results in dieting with rimonabant. Taking this into consideration I wish you lot’s of luck in your diet, and if you are already taking rimonabant and have some results please leave a comment and share your experience with all of us.
